South Korea’s Samsung Biologics announced on Monday that it signed a large contract manufacturing (CMO) deal worth $513.96 million (737.3 billion won) with a U.S.-based pharmaceutical company. This marks its second major order in 2025 to date and means Samsung Biologics has secured over half of its 2024 full-year order volume in just four months.

The deal accounts for 16.2 percent of Samsung Biologics’ consolidated sales in 2024. The contract spans six years and eight months and will run until December 31st, 2031. Due to confidentiality agreements, the client’s identity will be disclosed once the contract ends.

With this latest order, Samsung Biologics’ cumulative 2025 orders total 2.81 trillion won. Following record annual contract totals of 5.4 trillion won in 2024, the company is on track for another record-breaking year. Samsung Biologics previously secured its first-ever 2-trillion-won single contract with a European pharmaceutical company in January 2025.

A company official said, “Following the 2-trillion-won contract earlier in 2025, this is our second CMO order for the year. We will continue to strengthen our dominance as a global CMO leader.”

Samsung Biologics has increasingly secured “big deals” worth over 1 trillion won since 2024, landing three such contracts in 2024 alone. The company’s client base is also diversifying across the United States, Asia, and Europe, with 17 of the world’s top 20 global pharmaceutical companies now among its customers. Samsung Biologics plans to expand its client portfolio further in 2025 by targeting the top 40 pharmaceutical companies, with a particular focus on Japan and other Asian markets following the United States and Europe.

Samsung Biologics is also rapidly expanding its production capacity. The company recently started operating its fifth plant with a capacity of 180,000 liters, boosting its total capacity to 784,000 liters. It plans to add three more plants at its second bio campus by 2032 to hit a total capacity of 1,324,000 liters.

[ⓒ 매일경제 & mk.co.kr, 무단 전재, 재배포 및 AI학습 이용 금지]